Edwards Hits Snags With Trial Of Catheter-Delivered Heart Valve
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences is facing enrollment delays in its U.S. pivotal trial of a less invasive heart valve, though the company still says it will complete the patient sign-up effort by the end of next year
You may also be interested in...
Big Data In The Big Easy: Sapien Versus Surgery Results Get Top ACC Billing
Transcatheter aortic heart valve data, and Edwards Lifesciences' Sapien valve in particular, are set to take the spotlight at yet another major cardiology conference this weekend.
Big Data In The Big Easy: Sapien Versus Surgery Results Get Top ACC Billing
Transcatheter aortic heart valve data, and Edwards Lifesciences' Sapien valve in particular, are set to take the spotlight at yet another major cardiology conference this weekend.
Edwards Redesigns PARTNER Trial, Pushes Back Sapien Approval Timeline
Edwards Lifesciences has reached a verbal agreement with FDA on an amended design for the PARTNER trial of its Sapien transcatheter aortic valve, the company announced during its Dec. 7 2007 investor conference